Gland Pharma Limited - Asset Resilience Ratio
Gland Pharma Limited (GLAND) has an Asset Resilience Ratio of 0.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2026)
This chart shows how Gland Pharma Limited's Asset Resilience Ratio has changed over time. Check Gland Pharma Limited strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Gland Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Gland Pharma Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs737.41 Million | 0.59% |
| Total Liquid Assets | Rs737.41 Million | 0.59% |
Asset Resilience Insights
- Limited Liquidity: Gland Pharma Limited maintains only 0.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gland Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Gland Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Gland Pharma Limited (2018–2026)
The table below shows the annual Asset Resilience Ratio data for Gland Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.59% | Rs737.41 Million ≈ $7.97 Million |
Rs125.11 Billion ≈ $1.35 Billion |
-2.94pp |
| 2025-03-31 | 3.53% | Rs3.96 Billion ≈ $42.83 Million |
Rs112.25 Billion ≈ $1.21 Billion |
-11.31pp |
| 2024-03-31 | 14.84% | Rs15.82 Billion ≈ $171.05 Million |
Rs106.61 Billion ≈ $1.15 Billion |
-6.29pp |
| 2023-03-31 | 21.12% | Rs18.54 Billion ≈ $200.50 Million |
Rs87.78 Billion ≈ $949.26 Million |
-16.24pp |
| 2022-03-31 | 37.36% | Rs29.27 Billion ≈ $316.53 Million |
Rs78.34 Billion ≈ $847.18 Million |
-1.29pp |
| 2021-03-31 | 38.65% | Rs25.11 Billion ≈ $271.52 Million |
Rs64.96 Billion ≈ $702.53 Million |
+10.68pp |
| 2020-03-31 | 27.97% | Rs11.43 Billion ≈ $123.58 Million |
Rs40.86 Billion ≈ $441.89 Million |
+14.22pp |
| 2019-03-31 | 13.75% | Rs4.84 Billion ≈ $52.38 Million |
Rs35.24 Billion ≈ $381.06 Million |
+4.25pp |
| 2018-03-31 | 9.50% | Rs2.78 Billion ≈ $30.10 Million |
Rs29.29 Billion ≈ $316.81 Million |
-- |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic … Read more